miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study

The underlying in vivo mechanisms of rituximab action remain incompletely understood in chronic lymphocytic leukemia. Recent data suggest that circulating micro-ribonucleic acids correlate with chronic lymphocytic leukemia progression and response to rituximab. Our study aimed at identifying circula...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagez, Anne-Laure, Duroux-Richard, Isabelle, Leprêtre, Stéphane, Orsini-Piocelle, Frédérique, Letestu, Rémi, De Guibert, Sophie, Tuaillon, Edouard, Leblond, Véronique, Khalifa, Olfa, Gouilleux-Gruart, Valérie, Banos, Anne, Tournilhac, Olivier, Dupuis, Jehan, Jorgensen, Christian, Cartron, Guillaume, Apparailly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395115/
https://www.ncbi.nlm.nih.gov/pubmed/28126961
http://dx.doi.org/10.3324/haematol.2016.153189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395115/
https://www.ncbi.nlm.nih.gov/pubmed/28126961
http://dx.doi.org/10.3324/haematol.2016.153189

Ejemplares similares